GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Lexaria Bioscience
Lexaria Bioscience owns a patented technology for improving the delivery of active ingredients into the body. Its stock price is a bet that its DehydraTECH technology will be licensed to major pharmaceutical and consumer companies, which is its core business model.
Share prices of companies in the market segment - Pharma other
Lexaria Bioscience is a biotechnology company that developed the patented DehydraTECH technology to improve the delivery of active ingredients (APIs) into the body. We have classified it in the "Other Pharmaceuticals" category. The chart below shows how the market values innovative drug delivery platforms.
Broad Market Index - GURU.Markets
Lexaria Bioscience is a biotechnology company that owns the patented DehydraTECH technology, which improves the absorption of active pharmaceutical ingredients. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the broader market.
Change in the price of a company, segment, and market as a whole per day
LEXX - Daily change in the company's share price Lexaria Bioscience
Lexaria Bioscience Corp.'s daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its drug delivery technology.
Daily change in the price of a set of shares in a market segment - Pharma other
Lexaria Bioscience Corp. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with LEXX, with its unique drug delivery technology, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Lexaria Bioscience has developed a technology to improve the body's absorption of active substances, including cannabinoids. The company's shares are volatile and depend on research and partnership successes, contributing innovatively to the overall market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Lexaria Bioscience
For Lexaria Bioscience Corp., year-over-year performance is a story about its drug delivery technology. Its 12-month market cap hinges on success in clinical trials, where it must prove that its DehydraTECH technology can enhance the bioavailability of various drugs, from nicotine to cannabinoids.
Annual dynamics of market capitalization of the market segment - Pharma other
Lexaria Bioscience Corp. owns a patented technology that enhances the absorption of active ingredients, including cannabinoids. Its business model is based on licensing. Its stock price is extremely volatile, reflecting investor confidence in its breakthrough potential rather than current financial performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Lexaria, with its technology for improving drug absorption, is a speculative bet on the future of pharmaceuticals. Its stock price is unrelated to the economy, but driven by its technological breakthroughs and partnerships with major pharmaceutical companies. The chart tells the story of investors' faith that its innovation will become an industry standard.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Lexaria Bioscience
Lexaria Bioscience holds patents for its active ingredient delivery enhancement technology (DehydraTECH). Its monthly growth is driven by licensing agreements with companies in the pharmaceutical and consumer industries. Partnership news is a key driver.
Monthly dynamics of market capitalization of the market segment - Pharma other
This chart reflects the dynamics of the biotech sector. For Lexaria, with its unique drug delivery technology, it's the backdrop. Its movements show how partnerships with major pharmaceutical and consumer companies impact the valuation of its platform.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Lexaria Bioscience developed the patented DehydraTECH technology to improve the delivery of active ingredients (including cannabinoids and nicotine) into the body. The company's success depends on licensing agreements. The overall market chart provides only background; Lexaria shares are driven by news of partnerships and research results for its platform.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Lexaria Bioscience
Lexaria Bioscience, the owner of a patented technology for enhancing the delivery of active ingredients (APIs) into the body, is exhibiting speculative dynamics. Weekly share price fluctuations are a reaction to news of licensing agreements with pharmaceutical, tobacco, and consumer goods companies that may use its technology.
Weekly dynamics of market capitalization of the market segment - Pharma other
Lexaria Bioscience operates in the biotech sector, where shared technological breakthroughs and regulatory decisions impact everyone. The success of one company can boost the entire segment. The chart will show whether LEXX is perceived by the market as a promising platform player or simply part of the mainstream.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Lexaria Bioscience, as a biotech company, often ignores general market trends. Its fate depends not on GDP or inflation, but on licensing agreements. The chart below clearly demonstrates how LEXX shares can live their own life, separate from the broader market.
Market capitalization of the company, segment and market as a whole
LEXX - Market capitalization of the company Lexaria Bioscience
Lexaria Bioscience's market capitalization is a story about improving drug delivery. The company develops technology that enhances the bioavailability of active ingredients. Its valuation chart reflects how investors assess the potential of this platform for use in pharmaceuticals and consumer goods.
LEXX - Share of the company's market capitalization Lexaria Bioscience within the market segment - Pharma other
Lexaria Bioscience has developed a patented technology, DehydraTECH, which improves the absorption of active pharmaceutical ingredients, including cannabinoids. Its market share in the pharmaceutical sector is based on the potential of this platform. The chart shows how in-demand its technology is for the development of more effective and faster-acting drugs.
Market capitalization of the market segment - Pharma other
Lexaria Bioscience has developed a technology that improves the absorption and taste of active pharmaceutical ingredients, including cannabinoids. The graph below shows the market capitalization of the pharmaceutical sector. This represents innovations in drug delivery methods that can improve their effectiveness.
Market capitalization of all companies included in a broad market index - GURU.Markets
Lexaria Bioscience developed DehydraTECH, a technology that improves the body's absorption of active substances such as cannabinoids and nicotine. Its market capitalization is a bet on this platform. The chart below shows the economic weight of companies with substance delivery technologies.
Book value capitalization of the company, segment and market as a whole
LEXX - Book value capitalization of the company Lexaria Bioscience
Lexaria Bioscience is based on patented technology. The company's book value reflects its intellectual property in the DehydraTECH™ technology, which improves the absorption of active substances (from nicotine to drugs), and its laboratory equipment. The chart below shows how the company deploys capital to apply its platform across various industries.
LEXX - Share of the company's book capitalization Lexaria Bioscience within the market segment - Pharma other
Lexaria Bioscience develops drug delivery technologies based on its R&D laboratories. The S_BCap_Seg graph shows its small share of the pharmaceutical sector's physical infrastructure, which is typical for an innovative technology platform.
Market segment balance sheet capitalization - Pharma other
Lexaria Bioscience has developed a technology to improve the absorption of active ingredients (DehydraTECH). Its business is licensing this technology, not manufacturing finished products. The chart shows that it is a classic R&D company with "light" assets, where the main value is in patents.
Book value of all companies included in the broad market index - GURU.Markets
Lexaria's book value lies in its patented active substance delivery technology. The company's assets include its laboratories, processing equipment, and patent portfolio for the DehydraTECH™ technology. This material base allows for improving the absorption and effectiveness of a wide range of molecules, from nicotine to pharmaceuticals.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Lexaria Bioscience
Lexaria Bioscience has developed a patented technology, DehydraTECH, that improves the delivery of active substances (such as cannabinoids) into the body. Its book value is low. Its market capitalization is a valuation of this platform technology and its potential for licensing in the pharmaceutical and consumer industries.
Market to book capitalization ratio in a market segment - Pharma other
Lexaria Bioscience has developed a patented technology to improve the delivery of active substances (such as cannabinoids) into the body. Its value lies in this platform. The chart shows the premium the market is paying for the potential for licensing this technology in pharmaceuticals and consumer goods.
Market to book capitalization ratio for the market as a whole
Lexaria Bioscience has developed a patented technology that enhances the absorption of active substances, including cannabinoids and nicotine. The company's value lies in its platform technology, which can be licensed. The chart shows how the market values the potential of this technology, not its current tangible assets.
Debts of the company, segment and market as a whole
LEXX - Company debts Lexaria Bioscience
Lexaria Bioscience, a biotech company with a patented drug delivery technology, uses debt to fund research. This chart shows how the company is raising funds to conduct clinical trials of its technology with various substances, from nicotine to hypertension medications.
Market segment debts - Pharma other
Lexaria Bioscience has developed a patented technology to enhance the absorption of active substances (including cannabinoids and nicotine). As a technology company in the commercialization stage, it licenses its technology to other companies. This chart reflects its financial structure, which likely does not require significant debt to support its core operations.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Lexaria Bioscience
Lexaria Bioscience has developed a technology to improve the delivery of active ingredients into the body. This chart shows whether the company uses debt to fund its research and commercialization. For a company whose technology can be applied in pharmaceuticals and consumer goods, debt is a way to speed up market entry, but it comes with risks.
Market segment debt to market segment book capitalization - Pharma other
Lexaria Bioscience develops technologies to improve the delivery of active substances into the body, including for the pharmaceutical industry. This chart for the biotech sector shows how companies finance their platform technologies. It helps assess whether a company's debt represents an investment in a technology with broad applicability.
Debt to book value of all companies in the market
Lexaria Bioscience has developed a patented technology that improves the delivery of active substances (such as cannabinoids and nicotine) into the body. This chart, showing the market's debt-to-book value ratio, is important for assessing the investment climate in biotech. The market's willingness to finance innovative, but still-proven, technologies determines Lexaria's success.
P/E of the company, segment and market as a whole
P/E - Lexaria Bioscience
Lexaria Bioscience developed DehydraTECH, a technology that improves the body's absorption of active substances such as cannabinoids and nicotine. This graph depicts the potential of this platform technology. Its value demonstrates investors' belief that DehydraTECH will be licensed by many manufacturers to improve their own products.
P/E of the market segment - Pharma other
Lexaria Bioscience is a biotech company with a platform technology. This chart shows the average P/E for the biotech sector. A company's P/E is above average, suggesting that investors view its drug absorption-enhancing technology, DehydraTECH, as highly promising and applicable to a wide range of products.
P/E of the market as a whole
Lexaria Bioscience has developed a patented technology, DehydraTECH, which improves the absorption of active ingredients such as cannabinoids and nicotine. The company licenses its technology to other manufacturers. This chart shows sentiment in the pharmaceutical and consumer sectors. The company's valuation depends on the success of its partners and the signing of new licensing agreements, making it sensitive to the news environment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Lexaria Bioscience
Lexaria Bioscience developed the patented DehydraTECH technology to improve the delivery of active pharmaceutical ingredients (APIs) into the body. The graph reflects future revenue expectations, which depend on licensing this technology to pharmaceutical and consumer companies. This is a bet on the widespread adoption of their platform.
%20P%2FE%20Lexaria%20Bioscience&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Lexaria-Bioscience&v=1772558850821 "Chart of the company's future (projected) P/E Lexaria Bioscience")
Future (projected) P/E of the market segment - Pharma other
Lexaria Bioscience has developed a patented technology that improves the speed and efficiency of delivery of active substances (such as nicotine or cannabinoids) into the body. This chart shows how its future revenue expectations compare to the industry average, reflecting the potential of its platform across various industries.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772558850846 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
Lexaria Bioscience is a biotechnology company that owns the patented DehydraTECH technology, which improves the absorption of active pharmaceutical ingredients. The company's success depends on licensing agreements with pharmaceutical and consumer companies, rather than on general market cycles.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772558850887 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Lexaria Bioscience
Lexaria Bioscience developed the patented DehydraTECH technology to improve the bioavailability of active pharmaceutical ingredients, including nicotine and cannabinoids. The company's revenue depends on licensing this technology to other companies. This chart shows the company's financial trajectory as it strives to make its technology the standard in the pharmaceutical and consumer industries.
Profit of companies in the market segment - Pharma other
Lexaria Bioscience Corp. has developed a patented technology, DehydraTECH, that improves the speed and efficiency of active pharmaceutical ingredient (API) delivery. This graph reflects the profitability of the pharmaceutical sector. The company's technology can be applied in a variety of areas, from nicotine to medications. Its success depends on licensing agreements with major manufacturers.
Overall market profit
Lexaria Bioscience has developed a patented technology to improve the delivery of active substances (such as cannabinoids or nicotine) into the body. The company's success depends on licensing agreements with major manufacturers. This chart shows general market trends as Lexaria works to create value through innovation in pharmaceuticals and consumer products.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Lexaria Bioscience
Lexaria Bioscience has developed a patented technology, DehydraTECH, that enhances the absorption of active pharmaceutical ingredients, including cannabinoids. This graph reflects future revenue expectations, which depend on licensing agreements with pharmaceutical and consumer companies. It demonstrates the market's confidence in the potential of this platform technology.
%20profit%20of%20the%20company%20Lexaria%20Bioscience&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Lexaria-Bioscience&v=1772558851003 "Graph of future (projected) profit of the company Lexaria Bioscience")
Future (predicted) profit of companies in the market segment - Pharma other
Lexaria Bioscience Corp. owns the patented DehydraTECH technology for improving the bioavailability of active pharmaceutical ingredients, including cannabinoids. This chart shows profitability forecasts for the pharmaceutical sector. It reflects expectations for drug delivery technologies that can improve the effectiveness of existing drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772558851032 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
Lexaria Bioscience develops technologies to improve drug delivery. Like many biotech companies, their overall market revenue forecast is important for their investment climate. Expected economic growth facilitates raising the capital needed for research and commercialization of their DehydraTECH technology.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772558851057 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Lexaria Bioscience
Lexaria Bioscience has developed a technology to improve the delivery of active substances (including cannabinoids and nicotine) into the body. Revenue is dependent on licensing agreements with other companies. The price/sale reflects the market perception of the potential of its patented DehydraTECH platform for use in pharmaceuticals and consumer goods.
P/S market segment - Pharma other
Lexaria Bioscience developed the patented DehydraTECH technology, which improves the body's absorption of active pharmaceutical ingredients, including cannabinoids. Their revenue comes from licensing fees. The chart shows how the market perceives the potential of their drug delivery technology for use in pharmaceuticals and consumer goods.
P/S of the market as a whole
Lexaria Bioscience has developed a technology that improves the delivery of active substances (including cannabinoids and nicotine) into the body. Revenue is dependent on licensing this technology to other companies. This chart illustrates the average revenue estimate, which helps understand how the market values the company developing the platform technology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Lexaria Bioscience
Lexaria Bioscience has developed a patented technology, DehydraTECH, that improves the absorption of active pharmaceutical ingredients, including cannabinoids. This chart reflects investor expectations for future revenue from licensing this technology to pharmaceutical and consumer companies seeking to improve their products.
%20P%2FS%20Lexaria%20Bioscience&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Lexaria-Bioscience&v=1772558851137 "The graph of the company's future (projected) P/S Lexaria Bioscience")
Future (projected) P/S of the market segment - Pharma other
Lexaria Bioscience Corp. has developed a patented technology, DehydraTECH, that improves the delivery of active pharmaceutical ingredients into the body. This chart shows how the market estimates future revenue from licensing its technology. It compares it to other pharmaceutical companies, reflecting the potential of its platform to improve existing and new drugs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772558851160 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
Lexaria Bioscience has developed a proprietary technology to improve the delivery of active substances (such as cannabinoids or nicotine) into the body. It is a platform technology with broad potential applications. This chart illustrates general revenue expectations, and LEXX demonstrates how innovations in pharmaceutical delivery can open new markets.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772558851181 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Lexaria Bioscience
Lexaria Bioscience has developed a patented drug delivery technology, DehydraTECH™, which improves the absorption of active ingredients. The company's revenue, shown in this chart, is generated not from sales of its own products, but from licensing this technology to other companies in the pharmaceutical and consumer industries.
Sales of companies in the market segment - Pharma other
Lexaria Bioscience has developed a patented technology for enhancing the delivery of active ingredients (DehydraTECH). This chart segments its revenue, showing revenue from licensing this technology to various industries, such as pharmaceuticals and consumer goods. This reflects the broad application of its innovation.
Overall market sales
Lexaria Bioscience is developing technology to improve the delivery of active substances (including cannabinoids) into the body. Its revenue potential depends on licensing agreements with pharmaceutical and consumer companies. This timetable is not key; more important is proving the technology's effectiveness and securing partnerships.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Lexaria Bioscience
Lexaria Bioscience developed DehydraTECH technology to improve the delivery of active substances (including cannabinoids and nicotine) into the body. Its revenue forecast depends on licensing agreements with companies in the pharmaceutical and consumer industries. This chart shows the expected commercialization of its platform.
%20sales%20of%20the%20company%20Lexaria%20Bioscience&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Lexaria-Bioscience&v=1772558851291 "Schedule of future (projected) sales of the company Lexaria Bioscience")
Future (projected) sales of companies in the market segment - Pharma other
Lexaria Bioscience has developed a patented technology to improve the delivery of active pharmaceutical ingredients (APIs) into the body. This graph shows projected revenues for the entire pharmaceutical sector. It reflects the industry's need for innovative drug delivery methods, creating opportunities for licensing Lexaria's technology to other pharmaceutical companies.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772558851311 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Lexaria Bioscience developed DehydraTECH technology to improve the delivery of active ingredients (including cannabinoids and nicotine) into the body. The company's success depends on licensing agreements with major manufacturers. This business outlook reflects the companies' willingness to invest in R&D and innovative products, fueling interest in Lexaria's technology.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772558851327 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Lexaria Bioscience
Lexaria Bioscience has developed a patented technology, DehydraTECH, to improve the delivery of active pharmaceutical ingredients (APIs). This graph shows the path to monetization of this innovation. The company's profitability will depend on the successful licensing of its technology to pharmaceutical and consumer companies.
Market segment marginality - Pharma other
Lexaria Bioscience has developed a patented technology, DehydraTECH, that improves the speed and efficiency of active pharmaceutical ingredient delivery. This graph shows the average profit margin for biotech companies. It allows us to estimate how licensing this platform technology could provide Lexaria with above-industry profitability.
Market marginality as a whole
Lexaria Bioscience Corp. owns a patented technology for enhancing the delivery of active ingredients (DehydraTECH), which has potential applications in pharmaceuticals and consumer goods. This total revenue chart does not reflect the company's potential, which depends on licensing agreements with major players in various industries.
Employees in the company, segment and market as a whole
Number of employees in the company Lexaria Bioscience
Lexaria Bioscience has developed a patented technology to improve the delivery of active substances (such as cannabinoids) into the body. Its small scientific team is dedicated to researching and licensing this technology. This graph illustrates how a small R&D company can create value through intellectual property.
Share of the company's employees Lexaria Bioscience within the market segment - Pharma other
Lexaria Bioscience Corp. developed the patented DehydraTECH technology to improve the bioavailability of active pharmaceutical ingredients. This chart illustrates its innovative contribution to pharmacology. It reflects the number of chemists and pharmaceutical technologists working to improve drug delivery methods that Lexaria brings together under its umbrella.
Number of employees in the market segment - Pharma other
Lexaria Bioscience Corp. owns the patented DehydraTECH technology, which improves the delivery of active pharmaceutical ingredients. This chart shows overall employment in the pharmaceutical industry. Growth in this sector reflects the ongoing search for ways to improve the bioavailability and efficacy of drugs, creating demand for innovative delivery platforms like Lexaria's.
Number of employees in the market as a whole
Lexaria Bioscience Corp. has developed a patented drug delivery technology, DehydraTECH™, which improves the absorption of active ingredients. Innovations in pharmaceuticals are creating new opportunities for the entire industry. This chart illustrates the overall employment landscape, where biotech platforms like Lexaria can become growth catalysts for many companies.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Lexaria Bioscience (LEXX)
Lexaria Bioscience has a patented active ingredient delivery technology, a valuable intellectual property. This chart shows how the market perceives the potential of this platform technology, which can be applied across various industries. The high cost per employee is a premium for versatility and scientific innovation.
%20of%20the%20company%20Lexaria%20Bioscience%20(LEXX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Lexaria-Bioscience-LEXX&v=1772558851474 "Chart of market capitalization per employee (in thousands of dollars) of the company Lexaria Bioscience (LEXX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
Lexaria Bioscience has developed a patented technology for improving drug delivery. Its market capitalization per employee reflects the market valuation of this platform's potential. This high value suggests that investors see significant opportunities in licensing this technology to other pharmaceutical and consumer companies.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772558851491 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
Lexaria Bioscience has developed a patented technology to improve the delivery of active pharmaceutical ingredients (including cannabinoids) into the body. This technology platform is a key component of the Lexaria Bioscience platform. This chart reflects how the market perceives the potential of this technology, which could be licensed to multiple companies in the pharmaceutical and consumer industries.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772558851543 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Lexaria Bioscience (LEXX)
Lexaria Bioscience doesn't sell drugs, but rather owns a patented technology (DehydraTECH) for improving drug delivery. Its business is focused on R&D and licensing. This graph (likely negative) shows how much the company invests in each scientist to conduct research that will help it license its products to big pharma.
%20Chart%20Lexaria%20Bioscience%20(LEXX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Lexaria-Bioscience-LEXX&v=1772558851580 "Company Profit Per Employee (in thousands of dollars) Chart Lexaria Bioscience (LEXX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
Lexaria Bioscience developed the patented DehydraTECH technology to improve the delivery of active pharmaceutical ingredients (APIs). This graph demonstrates the value of their platform technology. It illustrates how effectively the company can license its technology to various industries, generating high revenues with a small team, which demonstrates its scalability.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772558851619 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
Lexaria Bioscience developed the patented DehydraTECH technology to improve the delivery of active substances (e.g., cannabinoids, nicotine) into the body. Their business is focused on R&D and licensing. This chart shows how efficiently the team generates revenue from licensing agreements compared to the R&D costs of this platform technology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772558851677 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Lexaria Bioscience (LEXX)
Lexaria Bioscience develops technology to improve the delivery of active ingredients into the body. This chart reflects its licensing business model. Revenue per employee depends on agreements with pharmaceutical and consumer companies. Growth in this figure will indicate widespread acceptance and adoption of its technology.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Lexaria-Bioscience-LEXX&v=1772558851728 "Sales chart per company employee Lexaria Bioscience (LEXX)")
Sales per employee in the market segment - Pharma other
Lexaria Bioscience (LEXX) develops the patented DehydraTECH technology to improve the delivery of active pharmaceutical ingredients (APIs), including cannabinoids, into the body. This chart shows the average revenue per employee in the pharmaceutical segment. Comparing LEXX to this benchmark demonstrates how efficiently they license their technology to other companies, as they do not sell finished products themselves.
Sales per employee for the market as a whole
Lexaria Bioscience (LEXX) is a biotech company that owns a patented drug delivery enhancement technology (DehydraTECH). They don't sell the final product, but license their technology. This figure should be high, as their business is R&D and IP licensing, which requires few personnel to generate royalties.
Short shares by company, segment and market as a whole
Shares shorted by company Lexaria Bioscience (LEXX)
Lexaria Bioscience is a company promoting a technology (DehydraTECH) that claims to improve the body's absorption of active substances, such as nicotine or cannabinoids. This chart shows that investors consider this a dud. Bears are betting that the company lacks compelling scientific data and will be unable to license its technology to major players.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Lexaria-Bioscience-LEXX&v=1772558851954 "Short Shares Chart for the Company Lexaria Bioscience (LEXX)")
Shares shorted by market segment - Pharma other
Lexaria (LEXX) doesn't produce drugs, but owns a technology (DehydraTECH) that it claims improves drug delivery (for example, for cannabinoids). This chart highlights the pessimism in the sector. The surge in shorts across the industry is a bet that such "platform" technologies don't work. Investors doubt DehydraTECH is a breakthrough and don't believe large pharma companies will line up to license it.
Shares shorted by the overall market
Lexaria Bioscience owns a patent (DehydraTECH) for improving the delivery of active ingredients (including cannabinoids) into the body. Their business model is licensing. This chart illustrates the general fear. When investors are fearful, they doubt the ability of small companies to secure large licensing deals. They worry that LEXX's clients won't pay for the technology in a downturn.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Lexaria Bioscience (LEXX)
Lexaria Bioscience (LEXX) owns the patented DehydraTECH technology, which improves the delivery of active substances (such as nicotine or cannabinoids) into the body. This is a business-to-business technology. This chart measures price momentum. It helps identify when the stock is "overheated" (above 70) on licensing news or "oversold" (below 30) due to a lack of new deals.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Lexaria-Bioscience-LEXX&v=1772558852049 "RSI 14 indicator chart for the company's stock Lexaria Bioscience (LEXX)")
RSI 14 Market Segment - Pharma other
Lexaria (LEXX) owns a patented technology (DehydraTECH) that improves the delivery of active ingredients (from nicotine to medications) into the body, making them more bioavailable. This chart tracks overall sentiment in the Pharmaceuticals sector. It helps investors understand whether LEXX's performance reflects their platform or whether the entire industry is overheated or oversold.
RSI 14 for the overall market
Lexaria Bioscience (LEXX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast LEXX (Lexaria Bioscience)
Lexaria Bioscience is a biotechnology company that developed DehydraTECH technology. This platform improves the delivery (absorption) of active ingredients (APIs), including cannabinoids and nicotine. This chart shows the speculative average price target from analysts based on their belief in the commercialization of this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-LEXX-Lexaria-Bioscience&v=1772558852156 "A chart showing analyst consensus forecasts for the expected stock price. LEXX (Lexaria Bioscience)")
The difference between the consensus estimate and the actual stock price LEXX (Lexaria Bioscience)
Lexaria is a "platform" company. Its DehydraTECH technology is designed to make medications (from nicotine to GLP-1) more bioavailable (better absorbed). This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their confidence in this R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-LEXX-Lexaria-Bioscience&v=1772558852177 "A chart showing the difference between the consensus forecast and the actual stock price. LEXX (Lexaria Bioscience)")
Analyst consensus forecast for stock prices by market segment - Pharma other
Lexaria Bioscience is a biotech company that has developed a "delivery" technology (DehydraTECH), which it claims improves the absorption of medications (from nicotine to GLP-1). This chart shows general expectations for the pharmaceutical sector. It reflects whether experts believe in R&D "delivery" platforms, not just the drugs themselves.
Analysts' consensus forecast for the overall market share price
Lexaria Bioscience is the owner of a patented technology (DehydraTECH) that improves the absorption (bioavailability) of various substances, including nicotine and cannabinoids. This chart shows the overall "risk appetite" in the market. For Lexaria, whose business is licensing technology, the overall optimism is important because it reflects the willingness of pharmaceutical and nicotine companies to invest in R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Lexaria Bioscience
Lexaria is a delivery technology. They don't have their own drugs; their signature feature is DehydraTECH, a patented technology (powder) that they claim accelerates the absorption of any drug (from nicotine to cannabis) into the body. This chart is a pure indicator of their R&D. It reflects their (slow) path to licensing this technology to big pharma.
AKIMA Market Segment Index - Pharma other
Lexaria Bioscience (LEXX) is a biotech company that owns the patented DehydraTECH drug delivery technology. This technology improves the absorption and bioavailability of active ingredients (e.g., cannabinoids, nicotine). The chart shows the average index for the segment, helping investors assess how this platform technology compares to the average.
The AKIM Index for the overall market
Lexaria Bioscience is a biotech company that owns DehydraTECH technology for improving drug delivery and absorption (nicotine, cannabinoids, GLP-1). This chart, which reflects the market average, is a backdrop. It helps assess how this licensed platform compares to overall macroeconomic trends and pharma interest.
